Rhumbline Advisers Annexon, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Annexon, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 135,998 shares of ANNX stock, worth $699,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,998

Previous 126,659 7.37%

Holding current value

$699,029

Previous $620,000 29.84%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.49 - $7.2 $41,932 - $67,240	9,339 Added 7.37%	135,998 $805,000
Q2 2024 Aug 01, 2024	BUY	$4.33 - $6.79 $193,468 - $303,383	44,681 Added 54.5%	126,659 $620,000
Q1 2024 May 09, 2024	BUY	$4.03 - $7.81 $91,311 - $176,958	22,658 Added 38.2%	81,978 $587,000
Q4 2023 Feb 08, 2024	SELL	$1.63 - $4.63 $635 - $1,805	-390 Reduced 0.65%	59,320 $269,000
Q3 2023 Nov 09, 2023	BUY	$2.13 - $3.84 $9,968 - $17,971	4,680 Added 8.5%	59,710 $140,000
Q2 2023 Aug 08, 2023	BUY	$2.1 - $6.37 $115,563 - $350,541	55,030 New	55,030 $193,000
Q2 2022 Aug 11, 2022	SELL	$2.11 - $4.06 $82,114 - $158,003	-38,917 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.73 - $11.94 $3,117 - $13,635	1,142 Added 3.02%	38,917 $106,000
Q4 2021 Feb 10, 2022	SELL	$11.49 - $22.0 $5,813 - $11,132	-506 Reduced 1.32%	37,775 $434,000
Q3 2021 Nov 12, 2021	BUY	$16.35 - $23.4 $24,116 - $34,515	1,475 Added 4.01%	38,281 $712,000
Q2 2021 Aug 05, 2021	BUY	$17.81 - $27.48 $203,212 - $313,546	11,410 Added 44.93%	36,806 $829,000
Q1 2021 May 06, 2021	BUY	$22.0 - $35.01 $211,706 - $336,901	9,623 Added 61.01%	25,396 $707,000
Q4 2020 Feb 10, 2021	BUY	$20.81 - $30.55 $55,292 - $81,171	2,657 Added 20.26%	15,773 $395,000
Q3 2020 Nov 12, 2020	BUY	$17.5 - $30.23 $229,530 - $396,496	13,116 New	13,116 $396,000

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $245M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Annexon, Inc. Transaction History